Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000019617-25-000437
Filing Date
2025-05-05
Accepted
2025-05-05 14:03:05
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5272
  Complete submission text file 0000019617-25-000437.txt   7259
Mailing Address 383 MADISON AVENUE NEW YORK NY 10017
Business Address 383 MADISON AVENUE NEW YORK NY 10017 2122706000
JPMORGAN CHASE & CO (Filed by) CIK: 0000019617 (see all company filings)

EIN.: 132624428 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91484 | Film No.: 25912229
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)